Skip to main navigation
Avadel Pharmaceuticals
  • Recent News
  • Investors
  • About
    • Overview
    • Leadership
    • Board of Directors
    • Business Development
    • Corporate Responsibility
  • Research
    • Clinical Trials
  • Contact Us
  • Call Today
  • Email Us
  • Our Map
    • Avadel Pharmaceuticals
    • 636.449.1830
    • Home
    • About
      • Overview
      • Leadership
      • Board of Directors
      • Business Development
      • Corporate Responsibility
    • Research Pipeline
      • Clinical Trials
    • Investor Relations

      • Investors
      • News & Events
        • Press Releases
        • Events
        • Presentations
      • Stock Information
        • Stock Quote & Chart
        • Historical Price Lookup
        • Investment Calculator
        • Analyst Coverage
      • Financial Information
        • SEC Filings
        • Financial Reports
        • Quarterly Results
      • Corporate Governance
        • Governance Highlights
        • Management Team
        • Board of Directors
        • Committee Composition
        • Annual General Meeting
      • Shareholder Services
        • Investor FAQs
        • Information Request
        • E-mail Alerts
        • IR Contacts
    • Contact Us
646.449.1830

Breadcrumb

  1. Home
  2. Investors
  3. Press Releases
  4. Avadel Pharmaceuticals to Present at BIO Digital

Press Releases

Printer Friendly Version View printer-friendly version << Back
June 8, 2020 at 8:00 AM EDT

Avadel Pharmaceuticals to Present at BIO Digital

PDF Version

DUBLIN, Ireland, June 08, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in patients with narcolepsy, today announced that Greg Divis, Chief Executive Officer of Avadel, and Jordan Dubow, M.D., Chief Medical Officer of Avadel, will present a corporate overview at BIO Digital from June 8-12, 2020.

The presentation will focus on the development of once-nightly FT218 and positive results from the Phase 3 Rest-On clinical trial. The presentation will be available on-demand during the conference via https://www.bio.org/events/bio-digital/sessions/693802.

About Avadel Pharmaceuticals plc:
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is an emerging biopharmaceutical company. The Company’s primary focus is the development and potential FDA approval of FT218, which has completed a Phase 3 clinical trial for the treatment of narcolepsy patients suffering from excessive daytime sleepiness (EDS) and cataplexy. In addition, Avadel markets a portfolio of sterile injectable drugs used in the hospital setting. For more information, please visit www.avadel.com. 

Contacts:
  Investor Contacts
Tom McHugh
Chief Financial Officer
Phone: (636) 449-1843
Email: tmchugh@avadel.com 
   
  Tim McCarthy
LifeSci Advisors, LLC
Phone: (212) 915.2564
Email: tim@lifesciadvisors.com 
   
  Media Contact
Patrick Bursey
LifeSci Communications, LLC
Phone: (646) 970-4688
Email: pbursey@lifescicomms.com 


Logo.png

Source: Avadel Pharmaceuticals plc

Tools

  • Print Page
  • RSS
  • E-mail Alerts

Investor Relations

  • Investors
  • News & Events
    • Press Releases
    • Events
    • Presentations
  • Stock Information
    • Stock Quote & Chart
    • Historical Price Lookup
    • Investment Calculator
    • Analyst Coverage
  • Financial Information
    • SEC Filings
    • Financial Reports
    • Quarterly Results
  • Corporate Governance
    • Governance Highlights
    • Management Team
    • Board of Directors
    • Committee Composition
    • Annual General Meeting
  • Shareholder Services
    • Investor FAQs
    • Information Request
    • E-mail Alerts
    • IR Contacts

Contact Avadel Pharmaceuticals Today

Avadel Pharmaceuticals

Helpful Links Site Map | Privacy Policy | Terms and Conditions

  • Overview
  • News & Events
  • Careers
  • Investors
  • Contact Us
16640 Chesterfield Grove Road,
Suite 200,
Saint Louis, MO 63005 |  View Map [+]
http://www.avadel.com/
Site Map | Privacy Policy
http://www.avadel.com/

© COPYRIGHT AVADEL PHARMACEUTICALS, PLC. ALL RIGHTS RESERVED

0117 AVL WBST MAIN_KP2